Literature DB >> 7032590

Characterization of a respiratory mutant of Escherichia coli with reduced uptake of aminoglycoside antibiotics.

M E Muir, D R Hanwell, B J Wallace.   

Abstract

A strain of Escherichia coli (NSW77) which is partially resistant to streptomycin was isolated by selecting for growth on plates supplemented with 12.5 micrograms/ml streptomycin, a concentration which completely inhibits growth of wild-type strains. The low-level resistance of the mutant appears to result from a reduced ability to accumulate streptomycin intracellularly. In addition, the mutant strain is unable to use succinate for growth because of a defective respiratory chain. Thus, membranes of the mutant strain were found to have approximately half the NADH and D-lactate oxidase activity of the parent strain. Moreover, membranes of the mutant were found to contain demethyl-menaquinone and, in place of ubiquinone, a structural analogue, 2-octaprenyl-3-methyl-6-methoxy-1,4 benzoquinone. The mutation responsible for both the Suc-phenotype and partial resistance to streptomycin was found to be located near minute 15 on the bacterial chromosome. Both the biochemical and genetic evidence suggests the the mutation in strain NSW77 resides in the ubi F gene. Another previously characterized ubi F strain was also found to have a reduced capacity to take up an aminoglycoside antibiotic (gentamicin). These results suggest that the respiratory defects in ubi F strains are responsible for the reduced capacity of such strains to accumulate aminoglycosides.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7032590     DOI: 10.1016/0005-2728(81)90232-2

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  8 in total

1.  Mutations in aarE, the ubiA homolog of Providencia stuartii, result in high-level aminoglycoside resistance and reduced expression of the chromosomal aminoglycoside 2'-N-acetyltransferase.

Authors:  M R Paradise; G Cook; R K Poole; P N Rather
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

Review 2.  Bacterial uptake of aminoglycoside antibiotics.

Authors:  H W Taber; J P Mueller; P F Miller; A S Arrow
Journal:  Microbiol Rev       Date:  1987-12

Review 3.  Destination of aminoglycoside antibiotics in the 'post-antibiotic era'.

Authors:  Yoshiaki Takahashi; Masayuki Igarashi
Journal:  J Antibiot (Tokyo)       Date:  2017-10-25       Impact factor: 2.649

4.  The conserved GTPase LepA contributes mainly to translation initiation in Escherichia coli.

Authors:  Rohan Balakrishnan; Kenji Oman; Shinichiro Shoji; Ralf Bundschuh; Kurt Fredrick
Journal:  Nucleic Acids Res       Date:  2014-11-06       Impact factor: 16.971

5.  Potential for the Development of a New Generation of Aminoglycoside Antibiotics.

Authors:  A N Tevyashova; K S Shapovalova
Journal:  Pharm Chem J       Date:  2022-01-13       Impact factor: 0.837

6.  Characterization of Escherichia coli D-cycloserine transport and resistant mutants.

Authors:  Gary Baisa; Nicholas J Stabo; Rodney A Welch
Journal:  J Bacteriol       Date:  2013-01-11       Impact factor: 3.490

7.  Biosynthesis of Menaquinone (Vitamin K2) and Ubiquinone (Coenzyme Q).

Authors:  R Meganathan; Ohsuk Kwon
Journal:  EcoSal Plus       Date:  2009-08

8.  Collateral Sensitivity Interactions between Antibiotics Depend on Local Abiotic Conditions.

Authors:  Richard C Allen; Katia R Pfrunder-Cardozo; Alex R Hall
Journal:  mSystems       Date:  2021-11-30       Impact factor: 6.496

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.